Kiora Pharmaceuticals swings to Q3 net loss of $1.75 million
KPRX•Kiora Pharmaceuticals reported a third-quarter 2026 net loss of $1.75 million, compared with year-earlier net income of $26,806. Collaboration revenue was $1 million, and quarter-end cash and short-term investments totaled approximately $16.3 million.
1. Quarterly results
Kiora Pharmaceuticals swung to a third-quarter 2026 net loss of $1.75 million from net income of $26,806 a year earlier. Collaboration revenue from its KIO-301 agreement with CKD was $1 million, compared with none in the year-earlier quarter. Cash and short-term investments totaled approximately $16.3 million at quarter-end, with $2.2 million in collaboration, tax and other receivables.
2. KIO-401 plans
The company in-licensed KIO-401 rights outside Asia and plans a multinational Phase 3 registration trial for central retinal artery occlusion.
